News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,770 Results
Type
Article (286)
Company Profile (1)
Press Release (4483)
Section
Business (1316)
Career Advice (2)
Deals (228)
Drug Delivery (3)
Drug Development (447)
Employer Resources (1)
FDA (128)
Job Trends (156)
News (2143)
Policy (208)
Tag
Academia (19)
Alliances (366)
Alzheimer's disease (6)
Antibody-drug conjugate (ADC) (6)
Approvals (131)
Artificial intelligence (1)
Bankruptcy (1)
Best Places to Work (149)
Breast cancer (12)
Cancer (34)
Career advice (2)
CAR-T (4)
Cell therapy (6)
Clinical research (393)
Collaboration (5)
Compensation (1)
COVID-19 (9)
C-suite (4)
Data (25)
Diabetes (1)
Diagnostics (140)
Diversity, equity & inclusion (1)
Drug pricing (1)
Earnings (555)
Employer resources (1)
Events (577)
Executive appointments (7)
FDA (138)
Funding (1)
Gene therapy (2)
Government (24)
Healthcare (105)
Immunology and inflammation (4)
Infectious disease (9)
Inflammatory bowel disease (2)
Intellectual property (1)
Interviews (1)
IPO (97)
Job creations (15)
Job search strategy (2)
Legal (52)
Lung cancer (8)
Lymphoma (1)
Manufacturing (4)
Medical device (65)
Medtech (65)
Mergers & acquisitions (131)
Metabolic disorders (1)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuroscience (13)
NextGen: Class of 2025 (76)
Non-profit (64)
Northern California (28)
Opinion (1)
Patents (3)
People (308)
Phase I (109)
Phase II (158)
Phase III (177)
Pipeline (13)
Postmarket research (4)
Preclinical (46)
Rare diseases (1)
Real estate (29)
Regulatory (144)
Reports (3)
Research institute (20)
Resumes & cover letters (1)
Schizophrenia (4)
Southern California (20)
Startups (24)
Stomach cancer (1)
United States (150)
Vaccines (2)
Date
Today (2)
Last 7 days (7)
Last 30 days (32)
Last 365 days (382)
2025 (38)
2024 (381)
2023 (325)
2022 (431)
2021 (360)
2020 (291)
2019 (302)
2018 (224)
2017 (248)
2016 (226)
2015 (273)
2014 (203)
2013 (232)
2012 (243)
2011 (166)
2010 (141)
Location
Africa (7)
Arizona (1)
Asia (234)
Australia (24)
California (51)
Canada (10)
Connecticut (5)
Delaware (9)
Europe (484)
Florida (1)
Illinois (3)
Japan (17)
Maryland (10)
Massachusetts (9)
New Jersey (17)
North Carolina (2)
Northern California (28)
Ohio (2)
Pennsylvania (18)
South America (13)
Southern California (20)
Texas (14)
Utah (7)
Virginia (2)
Washington State (1)
4,770 Results for "nx prenatal".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. (NXDC) is pleased to announce a significant milestone.
June 21, 2024
·
1 min read
Press Releases
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
January 23, 2025
·
4 min read
Press Releases
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
December 19, 2024
·
8 min read
Press Releases
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
November 21, 2024
·
6 min read
Biotech Bay
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics, Inc. announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase, being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma.
June 16, 2024
·
9 min read
Press Releases
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
November 18, 2024
·
7 min read
Drug Development
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics, Inc. announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain.
June 10, 2024
·
4 min read
Biotech Bay
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton’s tyrosine kinase (BTK).
April 9, 2024
·
8 min read
Press Releases
Yourgene Health and Genetix Launch First Local Non-invasive Prenatal Testing Service in Colombia
October 2, 2024
·
1 min read
NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl).
March 5, 2024
·
1 min read
1 of 477
Next
